Mark Cuban’s war on America’s $5 trillion healthcare machine: ‘They can’t react as quickly’

Mark Cuban, the billionaire entrepreneur and investor, has expressed his strong discontent with the state of the American healthcare system, declaring it fundamentally flawed. In a recent episode of the Equity podcast, Cuban emphasized the lack of transparency in drug pricing, stating, "No one looks at the financial side of healthcare and says, 'This is the way it should work.'" He pointed out that when patients visit a doctor and receive a prescription, they often remain unaware of the potential costs involved, leading to uncertainty about affordability. Cuban identified pharmacy benefit managers (PBMs) as a key component of the problem, explaining that these third-party entities control the pricing of prescription medications in a way that obscures true costs. To combat this issue, he founded Cost Plus Drugs in 2022, aiming to revolutionize drug pricing by offering consumers straightforward pricing structures. "They price to market; we price based off of cost," Cuban highlighted, illustrating the dramatic difference in pricing. For instance, while a generic chemotherapy drug might retail for thousands at traditional pharmacies, it could be available for as low as $21 through Cost Plus Drugs. Cost Plus Drugs operates on a transparent model, selling medications directly to consumers at the manufacturer's cost, with a modest markup of 15%, a $5 pharmacy fee, and shipping costs included. Cuban also mentioned that the company is working on enabling customers to pick up their medications at local pharmacies. To understand the significance of Cuban's approach, it’s essential to recognize the reasons behind exorbitant drug prices in the U.S. The pharmaceutical industry defends its high pricing by asserting that substantial profits are necessary to fund the research and development of new drugs. However, critics argue that these inflated prices are often not proportionate to the actual costs of R&D. A study from 2021 revealed that revenues from the top 20 best-selling drugs were sufficient for companies to recover their R&D investments while still yielding significant profits. Cuban also pointed out that artificial shortages exacerbate the issue of high drug prices in the U.S. He noted that certain essential medications, including those used for pediatric cancer treatment, often experience shortages due to manufacturers intentionally limiting supply to increase prices. Although there is limited direct evidence of this kind of profiteering, it is evident that prices tend to spike during shortages. In response to these challenges, Cuban is taking matters into his own hands by establishing a state-of-the-art manufacturing facility in Dallas, which utilizes robotic technology to expedite production. "We created this factory where we can turn over a new drug in four hours and ship it out to hospitals," he explained, emphasizing the company's commitment to addressing shortages. While the margins on shipping drugs directly to patients are narrow, Cuban believes that the manufacturing side of Cost Plus Drugs can be more financially viable, ultimately leading the company closer to profitability. His strategy extends beyond merely providing affordable medications; he aims to fundamentally alter the way the healthcare system operates. Cuban has expressed a clear refusal to conform to the traditional models dominated by large companies, stating, "I’m not going to work the way they want to do it, because that’s not what’s best aligned for patients." He warns that even major players like Amazon, which has partnered with PBMs through its pharmacy services, may find themselves at a disadvantage because of these alliances. For aspiring entrepreneurs looking to challenge established companies, Cuban advises them to avoid dependence on traditional PBMs. "All of healthcare is basically an arbitrage. How can I just get a small percentage of a $5 trillion market through technology, pricing, whatever it may be?" Cuban’s experience underscores the importance of agility in the face of large, slow-moving competitors. "When you run with the elephants, there’s the quick and the dead," he said, stressing the need for adaptability and innovation to stay ahead in the industry.